News from janssen research & development, llc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

01 Oct, 2016, 07:00 BST New Phase 3 Data Show Significant Efficacy Versus Placebo And Superiority Of Guselkumab Versus Humira® In Treatment Of Moderate To Severe Plaque Psoriasis

Janssen Research & Development, LLC (Janssen) announced today findings from the first of three pivotal Phase 3 studies evaluating guselkumab, a...


08 Jun, 2016, 12:48 BST New Janssen Phase 3 Data in Patients With Moderately to Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression and Improves Signs and Symptoms Of Disease

Sirukumab One-year Radiographic Data Show Significant Inhibition of Joint Destruction Janssen Research & Development, LLC (Janssen) announced today...


22 Mar, 2016, 12:10 GMT Janssen Disease Interception Unit Advances A Growing Venture Portfolio Focused On Intercepting Diseases Prior To Onset

Janssen Research & Development, LLC (Janssen) announced today two new research agreements established through its Disease Interception Accelerator...


12 Feb, 2015, 11:00 GMT Janssen Launches Three New Research Platforms Focused on Redefining Healthcare

Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today the launch of three...


06 Nov, 2014, 11:26 GMT Janssen Collaborates to Further Evaluate SIRTURO® (bedaquiline) in New Multidrug-Resistant Tuberculosis Treatment Regimens

Janssen Research & Development, LLC (Janssen) today announced a collaboration with the International Union Against Tuberculosis and Lung Disease (The ...


24 Sep, 2013, 11:00 BST Latest Phase 3 Results Demonstrate Safety and Efficacy Profile of INVOKANA® (canagliflozin) as Add-On Therapy in the Treatment of Type 2 Diabetes in Adults

Janssen Research & Development, LLC (Janssen) today announced results from a new 52-week analysis of Phase 3 results showing INVOKANA®...


23 Aug, 2012, 13:00 BST Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis

Janssen Biologics (Ireland) announced today it has initiated the Phase 3 development program for sirukumab (CNTO 136) as part of a collaboration with ...


16 Jul, 2012, 21:05 BST Janssen Submits Applications Requesting Approval Of SIMPONI® In U.S. And Europe For Treatment Of Moderately To Severely Active Ulcerative Colitis

Janssen Biotech, Inc. and Janssen Biologics B.V. announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S....